Keith Westby net worth and biography

Keith Westby Biography and Net Worth

Keith Westby is Senior Vice President and Chief Operating Officer of Iveric Bio. Mr. Westby joined the Company in 2007 and has over 20 years of experience in program and strategic alliance management and manufacturing operations in biotechnology companies. Mr. Westby was most recently Senior Vice President, Development Operations. Prior to joining the Company, Mr. Westby worked at Pharmasset, Inc., as Director, Project and Alliance Management. He also served in positions of increasing responsibility at Eyetech Pharmaceuticals, including Director, Alliance & Project Management, leading multifunctional project teams in the New Drug Application filing and marketing approval of Macugen. Previously, Mr. Westby worked at Tunnell Consulting, where he was a Senior Consultant in the firm’s Life Sciences practice focused on manufacturing operations and process improvement. Mr. Westby holds a BS in applied physics from the State University of New York, College at Geneseo, a MS in engineering management from Drexel University, and a MBA degree from Columbia Business School.

What is Keith Westby's net worth?

The estimated net worth of Keith Westby is at least $1.54 million as of June 2nd, 2023. Mr. Westby owns 39,652 shares of IVERIC bio stock worth more than $1,538,498 as of June 7th. This net worth evaluation does not reflect any other assets that Mr. Westby may own. Learn More about Keith Westby's net worth.

How do I contact Keith Westby?

The corporate mailing address for Mr. Westby and other IVERIC bio executives is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. IVERIC bio can also be reached via phone at (609) 474-6755 and via email at [email protected]. Learn More on Keith Westby's contact information.

Has Keith Westby been buying or selling shares of IVERIC bio?

Over the course of the past ninety days, Keith Westby has sold $3,169,114.74 of IVERIC bio stock. Most recently, Keith Westby sold 20,000 shares of the business's stock in a transaction on Friday, June 2nd. The shares were sold at an average price of $37.87, for a transaction totalling $757,400.00. Following the completion of the sale, the chief operating officer now directly owns 39,652 shares of the company's stock, valued at $1,501,621.24. Learn More on Keith Westby's trading history.

Who are IVERIC bio's active insiders?

IVERIC bio's insider roster includes David Carroll (CFO), Pravin Dugel (EVP), Glenn Sblendorio (CEO), Christopher Simms (SVP), and Keith Westby (COO). Learn More on IVERIC bio's active insiders.

Are insiders buying or selling shares of IVERIC bio?

During the last year, IVERIC bio insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $240,500.00. During the last year, insiders at the sold shares 24 times. They sold a total of 469,613 shares worth more than $12,642,059.69. The most recent insider tranaction occured on June, 2nd when COO Keith Westby sold 20,000 shares worth more than $757,400.00. Insiders at IVERIC bio own 2.9% of the company. Learn More about insider trades at IVERIC bio.

Information on this page was last updated on 6/2/2023.

Keith Westby Insider Trading History at IVERIC bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/2/2023Sell20,000$37.87$757,400.0039,652View SEC Filing Icon  
5/1/2023Sell20,000$37.12$742,400.0039,652View SEC Filing Icon  
4/24/2023Sell18,782$30.07$564,774.7439,652View SEC Filing Icon  
4/21/2023Sell1,218$30.00$36,540.0039,652View SEC Filing Icon  
4/3/2023Sell40,000$26.70$1,068,000.0039,652View SEC Filing Icon  
3/2/2023Sell20,000$23.93$478,600.0039,652View SEC Filing Icon  
2/17/2023Sell15,000$25.05$375,750.0046,354View SEC Filing Icon  
1/3/2023Sell3,480$20.06$69,808.8086,354View SEC Filing Icon  
12/19/2022Sell6,740$21.51$144,977.4081,084View SEC Filing Icon  
12/12/2022Sell5,393$20.89$112,659.7769,565View SEC Filing Icon  
12/1/2022Sell10,030$22.96$230,288.8059,759View SEC Filing Icon  
11/1/2022Sell72,916$23.92$1,744,150.7269,128View SEC Filing Icon  
4/18/2022Sell10,000$16.63$166,300.0099,128View SEC Filing Icon  
4/5/2022Sell9,298$19.02$176,847.96109,128View SEC Filing Icon  
2/7/2022Sell10,000$15.00$150,000.00View SEC Filing Icon  
1/3/2022Sell12,278$16.39$201,236.42View SEC Filing Icon  
12/20/2021Sell4,516$15.44$69,727.04View SEC Filing Icon  
12/13/2021Sell4,517$14.74$66,580.58View SEC Filing Icon  
12/10/2021Sell3,614$14.53$52,511.42View SEC Filing Icon  
12/10/2020Sell3,676$6.96$25,584.96View SEC Filing Icon  
1/6/2020Sell293$8.07$2,364.5141,276View SEC Filing Icon  
12/13/2019Sell4,530$6.60$29,898.0045,106View SEC Filing Icon  
See Full Table

Keith Westby Buying and Selling Activity at IVERIC bio

This chart shows Keith Westby's buying and selling at IVERIC bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IVERIC bio Company Overview

IVERIC bio logo
IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.
Read More

Today's Range

Now: $38.80
Low: $38.60
High: $38.96

50 Day Range

MA: $33.34
Low: $23.77
High: $38.90

2 Week Range

Now: $38.80
Low: $8.85
High: $38.99


3,608,180 shs

Average Volume

3,204,329 shs

Market Capitalization

$5.35 billion

P/E Ratio


Dividend Yield